Human IL-5R Antibody - Benralizumab Biosimilar

Human IgG1 afucosylated - CAS #1044511-01-4

ABOUT

Anti-human IL-5R - Benralizumab biosimilar - CAS #1044511-01-4

Anti-hIL-5R-hIgG1fut is a biosimilar antibody of Benralizumab, a human interleukin-5 receptor (IL-5R) antibody that blocks IL-5 signaling. This monoclonal antibody (mAb) specifically targets the alpha subunit of the IL-5R. Benralizumab, also known as MEDI-563, is FDA-approved for the treatment of severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA).

More details More details


Anti-hIL-5R-hIgG1fut comprises the variable region of Benralizumab and the afucosylated/non-fucosylated IgG1 constant region of Benralizumab for high effector functions. 

This mAb can be used together with HEK-Blue™ IL-5 cells for screening and neutralization assays to block IL-5 signaling induced by recombinant human IL-5 (see figure).

 

Key features

  • Each lot is functionally tested and validated.
  • The complete sequence of the antibody construct was verified.
  • The absence of endotoxins is determined by the EndotoxDetect™ assay.

All products are for research use only, and not for human or veterinary use.

Binding of Anti-hIL-5R Benralizumab
Binding of Anti-hIL-5R Benralizumab

SPECIFICATIONS

Specifications

Target

IL-5R

Target species

Human

Applications

Neutralization assay (tested)

ELISA

Species
Human
Isotype
hIgG1fut
kappa
Recommended isotype control
Human IgG1fut Isotype Control Antibody
Clone
Benralizumab
CAS number
1044511-01-4
Synonyms
MEDI-563
Tag
Tag-free
Source
CHO (fucosylation-deficient)
Production details
Animal-free
Purification
Protein A
Formulation buffer

Sodium phosphate buffer with glycine, saccharose, and stabilizing agents

Preservative
Azide-free
Purity
≥95% (SDS-PAGE)
Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Endotoxin

Negative (tested using EndotoxDetect™ assay)

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hIL-5R-hIgG1fut
  • Cat code: 
    hil5r-mab13
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20°C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Benralizumab is a humanized, afucosylated IgG1 monoclonal antibody (mAb) designed to target the alpha chain of the human interleukin 5 receptor (IL-5Rα), expressed on eosinophils and basophils [1]. IL-5 plays a critical role in the survival, proliferation, and activation of eosinophils, which contribute to airway inflammation and exacerbations in eosinophilic asthma [2]. In addition to inhibiting interleukin-5 signaling, Benralizumab leads to eosinophil apoptosis through ADCC [1]. Benralizumab is FDA-approved for the treatment of severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA) [3].

 

References

1. Wechsler ME, et al., 2024. Benralizumab versus Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis. N Engl J Med. 390(10):911-921. 
2. Kolbeck R, et al., 2010. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 125(6):1344-1353.e2. 
3. Fasenra (benralizumab) US prescribing information; 2024. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761070s021lbl.pdf

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?